Drug or treatment

Tafasitamab clinical trials

• 21Clinical trials
• 12Countries

Newest trials

All recruiting trials (21)

• Tafasitamab and Rituximab for newly diagnosed follicular lymphoma

  This study tests a combination of tafasitamab and rituximab to treat adults with newly diagnosed follicular lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07731789

• Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL

  This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07582159

• NK cell therapy with epcoritamab and tafasitamab for relapsed or treatment‑resistant B‑cell lymphoma

  This trial will try whether adding donor-derived ONC-PluReceptor NK cells to the antibodies epcoritamab and tafasitamab helps control relapsed or refractory CD19/CD20-positive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07283679

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Tafasitamab for adults with primary immune thrombocytopenia or warm autoimmune hemolytic anemia

  This trial will try tafasitamab, an anti‑CD19 antibody, in adults with primary immune thrombocytopenia or warm autoimmune hemolytic anemia to see if it is safe and helps blood counts.

  Recruiting at 39 sites Phase 2 Incyte Corporation · Glendale, Arizona and 38 other locations · NCT07104565

• Tafasitamab with lenalidomide and rituximab for newly diagnosed follicular and marginal zone lymphoma

  This trial will test whether adding tafasitamab to rituximab and lenalidomide is safe and helps people newly diagnosed with follicular lymphoma or marginal zone lymphoma.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT06792825

• Using Tafasitamab and Lenalidomide for Large B-cell Lymphoma after CAR-T Therapy

  This study is testing if the combination of tafasitamab and lenalidomide can help people with Large B-cell Lymphoma who still have cancer after CAR-T therapy.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06760156

• Combining Tafasitamab and Lenalidomide with Gemcitabine and Oxaliplatin for treating relapsed DLBCL

  This study is testing a new combination of medications for people with relapsed DLBCL to see if it works better than the standard treatment.

  Recruiting at 3 sites Phase 3 Beijing InnoCare Pharma Tech Co., Ltd. · Beijing and 19 other locations · NCT06521255

• Continued treatment for patients with blood cancers using tafasitamab

  This study is testing if continuing treatment with tafasitamab can help patients with blood cancers who have already seen some improvement from the medication.

  Recruiting at 3 sites Phase 2 Incyte Corporation · Győr and 4 other locations · NCT06465433

• Combination treatment for autoimmune disorders using specialized cells and chemotherapy

  This study is testing a new combination of specialized cells and chemotherapy to see if it can help people with autoimmune disorders like systemic sclerosis and lupus feel better.

  Recruiting at 2 sites Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas and 1 other locations · NCT06434363

• Evaluating Tafasitamab with Lenalidomide for Relapsed DLBCL in Italy

  This study is testing if a combination of two medications, tafasitamab and lenalidomide, can help people in Italy with relapsed diffuse large B-cell lymphoma who can't have a transplant.

  Recruiting Incyte Biosciences Italy S.r.l · Milan · NCT06299553

• Combining Zanubrutinib and Tafasitamab for Mantle Cell Lymphoma

  This study is testing the best dose of a new combination treatment with Zanubrutinib and Tafasitamab to see if it helps people with mantle cell lymphoma manage their disease better.

  Recruiting Phase 1/2 University of Miami · Miami, Florida · NCT06029309

• Combination treatment for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma

  This study is testing a new combination of three medications to see if it can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma feel better and live longer.

  Recruiting Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT05943496

• Combination treatment for relapsed or refractory mantle cell lymphoma

  This study is testing a new combination of three drugs to see if it can help people with relapsed or refractory mantle cell lymphoma feel better and live longer.

  Recruiting Phase 2 Academic and Community Cancer Research United · Rochester, Minnesota and 1 other locations · NCT05910801

• Combining new drugs with standard treatment for relapsed large B-cell lymphoma

  This study is testing a new combination of drugs for people with large B-cell lymphoma that has come back or didn’t get better with earlier treatments to see if it works better than the usual options.

  Recruiting at 99 sites Phase 2 SWOG Cancer Research Network · Tucson, Arizona and 103 other locations · NCT05890352

• Combination treatment of tafasitamab and rituximab for post-transplant lymphoma

  This study is testing if a combination of two medications, tafasitamab and rituximab, can effectively treat lymphoma that develops after organ transplants.

  Recruiting at 4 sites Phase 2 Ohio State University Comprehensive Cancer Center · New Brunswick, New Jersey and 3 other locations · NCT05786040

• Combination treatment for relapsed B-cell lymphoma

  This study is testing a new combination of treatments for people with relapsed B-cell lymphoma to see if it helps them respond better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05615636

• Combination treatment for patients with primary central nervous system lymphoma

  This study is testing a new combination of treatments for adults with primary central nervous system lymphoma who can't have high-dose chemotherapy to see if it helps them get better and live longer.

  Recruiting Phase 2 University of Cologne · Stuttgart, Baden-Wurttemberg and 5 other locations · NCT05583071

• Combining Tafasitamab and Lenalidomide for treating relapsed DLBCL

  This study is testing if combining Tafasitamab and Lenalidomide can help people with relapsed or hard-to-treat Diffuse Large B-Cell Lymphoma feel better.

  Recruiting Phase 2 Beijing InnoCare Pharma Tech Co., Ltd. · Hangzhou, Zhejiang · NCT05552937

• Using Tafasitamab to treat children with relapsed or refractory acute B-lineage leukemia

  This study is testing a new treatment called Tafasitamab to see if it can help children with hard-to-treat acute leukemia stay healthy longer after their stem cell transplant.

  Recruiting at 8 sites Phase 1/2 University Hospital Tuebingen · Freiburg im Breisgau, Baden-Wurttemberg and 10 other locations · NCT05366218

• Combination treatment of Tafasitamab and Lenalidomide for relapsed CNS lymphoma

  This study is testing a combination of two drugs, Tafasitamab and Lenalidomide, to see if they can help people with relapsed central nervous system lymphoma feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 University of California, San Francisco · San Francisco, California · NCT05351593

Quick answers

How many clinical trials of Tafasitamab are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 12 countries. The most sites are in United States (15 trials), Italy (3 trials), Spain (2 trials), China (2 trials), Germany (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 12, Phase 1/2: 5, Phase 1: 2, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →